



**For Immediate Release**

**Contact:**

Cassie France-Kelly  
Public Relations, Martek  
(443) 542-2116  
[media@martek.com](mailto:media@martek.com)

**Martek Partners with Physician's DHA Choice, to Offer DHA Advantage™  
High-Dose *life'sDHA*™ Supplement Through Health Practitioners**

**COLUMBIA, Md. – February 19, 2009** – DHA omega-3 innovator and maker of the *life'sDHA*™ brand, Martek Biosciences Corporation (NASDAQ: MATK), announced today that Physicians DHA Choice LLC has launched DHA Advantage™, a 600 mg DHA daily dose for brain, eye and heart health featuring *life'sDHA*. DHA Advantage is available to consumers through their health care practitioners.

DHA Advantage is the first product to be launched by Physicians DHA Choice following the signing of a license and supply agreement between Martek and Physicians DHA Choice. Under the terms of the agreement, Physicians DHA Choice is distributing the Martek DHA omega-3 and is granted rights to sell DHA Advantage 600 mg daily dose with *life'sDHA* in the licensed health care practitioner channel.

"Martek is pleased to be working with Physicians DHA Choice as its partner in the health care practitioner channel," said David Abramson, president of Martek Biosciences. "DHA Advantage with *life'sDHA* offers a trusted, vegetarian source of DHA for brain, eye and heart health, at the highest recommended dosage currently on the market."

DHA (docosahexaenoic acid) omega-3 is a long-chain omega-3 fatty acid that serves as a primary building block for the brain and the eyes and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages, from infants to aging adults, benefit from an adequate supply of DHA omega-3 in the diet. Scientific reviews highlight the importance of DHA omega-3 in proper brain and eye development and function, and clinical studies are underway to evaluate the role of DHA in decreasing the prevalence of certain neurological disorders. Yet despite its importance, Americans have among the lowest dietary intakes of DHA omega-3 in the world.

Fish are often thought to be the only source of DHA omega-3. However, *life'sDHA* offers a trusted, vegetarian form of DHA that contains no oceanic pollutants and toxins. Fish are an abundant source of DHA because of the DHA-rich microalgae in their food chain; *life'sDHA* is derived from microalgae and produced in an FDA-inspected facility, from start to finish, using a sustainable source that does not deplete ocean resources. *life'sDHA* is found in numerous foods, beverages and supplements for people of all ages. It is also the only source of DHA used in U.S. infant formula and is available in more than 95 percent of the formulas on the U.S. market.

Physicians DHA Choice Practitioner Program is designed to give the licensed medical community the opportunity to offer the highest quality and most effective products using an Internet distribution model. DHA Advantage will be available to consumers only through licensed medical practitioners. Physicians DHA Choice

has plans to add additional products to the program in the near future. For more information on DHA Advantage™, visit <http://www.DHAadvantage.net>.

Martek Biosciences Corporation (NASDAQ: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces *life'sDHA*, a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, and supplements, and *life'sARA*™ (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks. For more information on Martek Biosciences, visit <http://www.martek.com/>. For a complete list of *life'sDHA* or *life'sARA* products, visit <http://www.lifesdha.com/>.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2008 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.